Alemtuzumab Is The Most Cost-Effective Option In Comparison To Available Therapies In The Treatment of Rrms From The UK NHS Perspective

OBJECTIVES: To estimate the cost-effectiveness/cost-utility (CEA) for alemtuzumab compared with other licensed disease-modifying therapies (DMTs) in the UK from the National Health Service (NHS) perspective. METHODS: The cost-effectiveness of alemtuzumab was evaluated in comparison to 11 DMTs with available 6-month confirmed disability worsening (CDW-6m) data over a lifetime horizon (i.e., 50 years). The population considered at least 80% of patients with RRMS. Direct costs considered were natural history, drug and treatment administration, monitoring, and adverse event management. Drug costs were obtained from the British National Formulary 2016 and MIMS drug database. Costs of treatment administration, monitoring, and adverse event management were acquired from NHS from 2014-2015 (annual fiscal costs). Effectiveness/utility was expressed as quality-adjusted life years (QALYs), life-years (LYs), number of relapses, and years without cane use (EDSS